Important items here.
Your access to personalized healthcare is under attack. The FDA is limiting 17 compounded therapies. Don't let them silence your voice. CLICK THE LINK to learn more and contact your legislators NOW: https://lnkd.in/gFX-uqru #EVEXIAS #EvexiPEL #HRT
District Sales Leader of Florida | ELEVATE WITH EVEXIAS: Proven therapies paired with complete business solutions to enhance patient care and practice growth.
Calling all provider and patients! It’s time to stand up for what’s right & make our voices heard to protect compounded therapies. We need your help. We need your voice. Visit the link below to learn more how you can help us stand up for what’s right! #protectpeptides
Your access to personalized healthcare is under attack. The FDA is limiting 17 compounded therapies. Don't let them silence your voice. CLICK THE LINK to learn more and contact your legislators NOW: https://lnkd.in/gFX-uqru #EVEXIAS #EvexiPEL #HRT
Drug shortages pose a significant challenge to the healthcare system, affecting patient care and treatment outcomes. The FDA plays a crucial role in managing and mitigating these shortages. This blog discusses the causes of drug shortages, the impact on healthcare, and how the FDA works to address and prevent them. Read more here: https://lnkd.in/e7nTTUCA
NAPCA’s latest Ask NAPCA Column #11 is here! In this month’s column, we address the recent changes to Medicare Part D, discussing potential impacts on drug costs and how the new legislation might affect certain medications. If you have any further questions, please call our Senior Assistance Center. #medicare
NAPCA’s latest Ask NAPCA Column #11 is here! In this month’s column, we address the recent changes to Medicare Part D, discussing potential impacts on drug costs and how the new legislation might affect certain medications. If you have any further questions, please call our Senior Assistance Center. #medicare
I help biotech and pharma companies bring their therapeutics to market and to patients through effective regulatory and scientific and medical communications strategies and deliverables.
The Psychopharmacologic Drugs Advisory Committee (PDAC), a group of independent experts which advises the FDA, yesterday recommended not to approve MDMA for PTSD. Several companies, including Lykos Therapeutics, are currently developing MDMA, for a range of mental health disorders, in this case, PTSD in veterans. In PDAC's opinion, MDMA combined with psychological intervention to treat PTSD in adults was not effective and the risks outweighed the benefits regarding the FDA's proposed risk evaluation and mitigation strategy (REMS). Although PDAC's guidance to the FDA is not binding, it typically follows it. This is the first psychedelics drug application to be submitted to the FDA for a mental health condition. Psychedelics biotech will be watching keenly at the FDA's decisions because the outcome will either be a game changer or a death knell for investment into the research space. In the US, ~13 million people live with PTSD, and existing treatments, including SSRIs, have been hit and miss. New treatment options are desperately needed. The decision date is Sunday 11th August 2024. Everything crossed for you Lykos Therapeutics 🤞🏾🤞🏾 #psychedelic #mdma #ptsd #lykostherapeutics #mapsbc #mentalhealth #mentalhealthconditions #fda
We are committed to working alongside the FDA to address outstanding questions to find a path forward ensuring the responsible and careful introduction of our investigational therapy into the healthcare system. https://lnkd.in/eVTwBXPg
Breaking: Today, the US FDA approved the first therapy for adults with #DesmoidTumors. We are thankful to the patients, physicians, advocates, and SpringWorkers who helped make this achievement possible. Watch this video from our CEO, Saqib Islam, to learn more about the significance of this approval. #RareDisease https://bit.ly/3SZUgby
The Supreme Court unanimously held on June 13, 2024, that the plaintiffs lacked standing to challenge FDA approvals of mifepristone, a medication used for, among other indications, the termination of certain pregnancies. Our latest blog post authored by Noam Fischman and Danielle Gordet, Esq., M.P.H. delves into the Court’s rationale and its implications for healthcare providers, including policies that EMTALA covered hospitals should be considering. #LegalUpdate #HealthcareLaw #FDA https://lnkd.in/ezBQKQQN
Are you curious about how Medicare Part D works? Our new blog demystifies this essential aspect of Medicare, offering insights into prescription drug plans, costs, and coverage. Learn how you can manage your healthcare expenses effectively with Medicare Part D. Stay informed and prepared for your healthcare needs. #MedicarePartD #PrescriptionCoverage #JMBFinancialManagers tinyurl.com/5a7uxw44
Learning what information #raredisease patients & their care partners find helpful in their decision-making when considering #genetherapy is crucial to the FDA. Share your perspective at our 9/20 virtual listening meeting. Registration is free: https://bit.ly/3XUEQrP
Help your patients navigate Medicare's complex landscape. Our FREE webinar will equip you with the tools you need to help them find the best plans for their needs during Open Enrollment. #Medicare #Pharmacy #PatientEducation #Webinar https://lnkd.in/e5J_d8rr